Tesamorelin vs AOD-9604: Which peptide is more effective for fat loss?

Tesamorelin currently appears to be a more clinically investigated and effective peptide for reducing visceral adipose tissue and improving metabolic health, whereas AOD-9604 remains a more experimental peptide primarily targeting fat metabolism and body weight reduction with less hormonal influence. In a „tesamorelin vs AOD-9604” comparison, tesamorelin possesses extensive clinical trial data supporting significant reductions in visceral adipose tissue (VAT), liver fat, and markers of metabolic risk, while AOD-9604 has shown a more moderate fat reduction potential in animal studies and smaller human obesity studies, but without a comparable amount of long-term clinical data and regulatory approval for obesity treatment [1–8].

Both peptides work in completely different ways in the body. Tesamorelin is a stabilised analogue of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release endogenous growth hormone (GH), which subsequently increases insulin-like growth factor-1 (IGF-1) levels and activates fat-burning pathways [1–3]. By activating the GH–IGF-1 axis, tesamorelin preferentially acts on visceral adipose tissue while improving lipid metabolism, reducing liver fat, supporting mitochondrial function, and improving body composition.

AOD-9604 works through a different mechanism. It is a modified fragment of human growth hormone corresponding to amino acids 176–191 and was designed to retain fat-burning properties without strongly increasing IGF-1 levels or activating the broader anabolic effects associated with GH [9–11]. Rather than strongly stimulating the entire GH hormonal system, AOD-9604 primarily enhances lipolysis and limits lipogenesis directly within fat tissue. Lipolysis means the breakdown of fat, whereas lipogenesis refers to the storage and creation of fat.

Tesamorelin has significantly stronger clinical evidence regarding fat reduction. In a pooled analysis of Phase III trials by Falutz et al. (2010), tesamorelin reduced visceral fat by approximately 15.4% over 26 weeks in HIV-positive individuals with abdominal fat accumulation, whilst improving triglyceride levels and cholesterol ratios [3]. Long-term extension studies demonstrated sustained reduction in abdominal fat for up to 52 weeks whilst continuing therapy [4]. Stanley et al. (2014) also demonstrated a significant reduction in both visceral adipose tissue and hepatic fat in HIV-positive individuals with excess abdominal fat [5]. In patients with HIV-associated NAFLD, Stanley et al. (2019) reported a relative reduction in hepatic fat of approximately 37% after 12 months of tesamorelin therapy [6]. These results suggest that tesamorelin primarily targets harmful visceral fat and hepatic fat, rather than solely promoting general weight loss.

AOD-9604 also demonstrated some fat-reducing activity, however, the available data are less consistent and less extensive. In studies on obese mice, Heffernan et al. (2001) showed that AOD-9604 increased fat oxidation and reduced body weight mainly through the activation of β3-adrenergic receptors without significantly increasing IGF-1 levels or worsening glucose metabolism [12,13]. Ng et al. (2000) similarly demonstrated that oral AOD-9604 reduced weight gain and improved fat metabolism in obese Zucker rats without inducing insulin resistance [14].

Some clinical trials regarding obesity have also yielded promising results. In a randomised, placebo-controlled trial described by Herd et al. (2005), obese adults receiving oral AOD-9604 achieved a modest but statistically significant reduction in body weight compared to placebo over 12 weeks [15]. However, subsequent larger trials did not replicate equally robust effects, and the development of AOD-9604 as an obesity therapy was ultimately limited [16]. Compared to tesamorelin, the evidence for long-term visceral fat reduction and metabolic health improvements remains significantly weaker.

One of the main differences between peptides is their effect on IGF-1 and the hormonal system. Tesamorelin increases endogenous GH and IGF-1 levels, which is likely responsible for its stronger effects in reducing visceral fat, protecting lean muscle mass, liver metabolism, and mitochondrial activity [1–6]. At the same time, this means the possibility of side effects associated with GH, such as water retention, oedema, joint pain, or minor changes in glucose levels.

AOD-9604 was designed specifically to avoid significantly increasing IGF-1 levels and broad hormonal stimulation [9–11]. Studies suggest that AOD-9604 does not significantly affect IGF-1 levels or worsen insulin sensitivity, which could be attractive for those seeking fat-burning support without stronger hormonal stimulation [11,17,18].

Tesamorelin also has stronger evidence for improving overall metabolic health beyond just fat loss. Clinical trials have shown improvements in triglycerides, cholesterol ratio, liver enzymes, inflammatory markers, mitochondrial function, and cardiovascular risk markers [3–6]. AOD-9604 appears to be more focused on fat metabolism and body weight reduction with no comparable evidence for broader metabolic or hepatic benefits. While preliminary studies suggest possible effects on fatty liver and bone health, these data remain largely preclinical [7–10].

The regulatory status also clearly distinguishes the two peptides. Tesamorelin has been approved by the FDA under the brand name Egrifta SV for the reduction of excess abdominal fat in HIV-associated lipodystrophy [1]. In contrast, AOD-9604 has not received FDA approval for the treatment of obesity or any other medical indication and remains primarily a research compound despite its presence in some wellness circles and peptide clinics [11]. Additionally, the World Anti-Doping Agency (WADA) classifies AOD-9604 as a prohibited substance for athletes, as it is still considered an experimental peptide [19].

In summary, tesamoretin currently appears to be a stronger option if the goal is clinically confirmed reduction of visceral fat, improvement of fatty liver, and support for metabolic health. AOD-9604 may offer a milder and more targeted fat-burning effect with less hormonal impact and minimal IGF-1 stimulation, however, its effects in humans are less consistent and significantly less well-established. The final choice depends on whether the priority is evidence-based improvement of metabolic health and reduction of visceral fat, or a more experimental approach focused primarily on fat metabolism with less hormonal impact.

Disclaimer

The content is for educational and scientific information purposes only and should not be interpreted as medical advice, diagnosis, or a therapeutic recommendation. Tesamorelin is an approved prescription medication for specific medical indications, whereas AOD-9604 remains an investigational compound and has not been approved by the FDA for obesity treatment. Peptides affecting fat metabolism and growth hormone pathways may carry risks and should only be used under the supervision of a qualified healthcare professional with appropriate medical evaluation and laboratory monitoring.